Century Therapeutics (IPSC) Non Operating Income (2022 - 2026)

Century Therapeutics (IPSC) has reported Non Operating Income for 5 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income fell 14.47% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $7.3 million (down 41.77% YoY), while the FY2025 annual figure was $7.6 million, down 42.96% from the prior year.
• Non Operating Income improved to $2.0 million in Q1 2026 per IPSC's latest filing, from $1.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.6 million in Q2 2024 and bottomed at $381000.0 in Q2 2022.
• Historically, Non Operating Income has averaged $2.4 million across 5 years, with a median of $2.3 million in 2025.
• Annual changes were most pronounced in 2023 — Non Operating Income surged 618.11% — and 2025, when it plunged 52.73%.
• Century Therapeutics' Non Operating Income stood at $1.7 million in 2022, then soared by 111.05% to $3.5 million in 2023, then decreased by 14.54% to $3.0 million in 2024, then slumped by 52.73% to $1.4 million in 2025, then jumped by 44.41% to $2.0 million in 2026.
• Business Quant data shows IPSC's Non Operating Income at $2.0 million in Q1 2026, $1.4 million in Q4 2025, and $1.7 million in Q3 2025.